2023-05-10 16:11:41 ET
- ADMA Biologics press release ( NASDAQ: ADMA ): Q1 GAAP EPS of -$0.03 beats by $0.01 .
- Revenue of $57M (+95.9% Y/Y) beats by $3.59M .
- 2023 Financial Guidance: ADMA now anticipates full year 2023 total revenues to exceed $220 million, vs. $212.36M consensus
- 2024-2025 Financial Guidance: The Company anticipates generating approximately $250 million or more in topline revenue in 2024, and approximately $300 million or more thereafter.
For further details see:
ADMA Biologics GAAP EPS of -$0.03 beats by $0.01, revenue of $57M beats by $3.59M